Education
About Us
Working with TipRanks
Follow Us
Alvin Shih Insider Profile
4 Followers
Alvin Shih, EVP of Research & Development at Travere Therapeutics, holds 20.00K shares in Zevra Therapeutics (Ticker: ZVRA), holds 184.58K shares in Travere Therapeutics (Ticker: TVTX). Most recently, Alvin Shih Bought ― shares of Zevra Therapeutics on Sep 15, 2025 for an estimated value of $157.80K.
Alvin Shih has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Alvin Shih holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Alvin Shih
Alvin Shih's Trading History
Travere Therapeutics
Sep 02, 2016
EVP of Research & Development
Uninformative Sell
142.01K
$4.47M
Zevra Therapeutics
Sep 15, 2025
Director
Informative Buy
157.80K
$158.80K
List of latest transactions for each holding click on a transaction to see Alvin Shih's performance on stock
You May Also Like
Alvin Shih insider profile FAQ
What is the percentage of profitable transactions made by Alvin Shih?
The percentage of profitable transactions made by Alvin Shih is ―.
What is the average return per transaction made by Alvin Shih?
The average return per transaction made by Alvin Shih is ―.
What stocks does Alvin Shih hold?
Alvin Shih holds: TVTX, ZVRA stocks.
What was Alvin Shih’s latest transaction?
Alvin Shih latest transaction was an Informative Buy of $157.80K.
What was Alvin Shih's most profitable transaction?
Alvin Shih’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Alvin Shih's role in Travere Therapeutics?
Alvin Shih's role in Travere Therapeutics is EVP of Research & Development.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.